Literature DB >> 27379379

Choline Ameliorates Disease Phenotypes in Human iPSC Models of Rett Syndrome.

Eunice W M Chin1,2,3, Guillaume Marcy1, Su-In Yoon4, Dongliang Ma1,2, Francisco J Rosales5, George J Augustine6, Eyleen L K Goh7,8,9,10.   

Abstract

Rett syndrome (RTT) is a postnatal neurodevelopmental disorder that primarily affects girls. Mutations in the methyl-CpG-binding protein 2 (MECP2) gene account for approximately 95 % of all RTT cases. To model RTT in vitro, we generated induced pluripotent stem cells (iPSCs) from fibroblasts of two RTT patients with different mutations (MECP2 (R306C) and MECP2 (1155Δ32)) in their MECP2 gene. We found that these iPSCs were capable of differentiating into functional neurons. Compared to control neurons, the RTT iPSC-derived cells had reduced soma size and a decreased amount of synaptic input, evident both as fewer Synapsin 1-positive puncta and a lower frequency of spontaneous excitatory postsynaptic currents. Supplementation of the culture media with choline rescued all of these defects. Choline supplementation may act through changes in the expression of choline acetyltransferase, an important enzyme in cholinergic signaling, and also through alterations in the lipid metabolite profiles of the RTT neurons. Our study elucidates the possible mechanistic pathways for the effect of choline on human RTT cell models, thereby illustrating the potential for using choline as a nutraceutical to treat RTT.

Entities:  

Keywords:  ChAT; Choline; Human iPSC; Lipid metabolite profile; MeCP2; Neutraceutical; Rett syndrome; Synaptic functions

Mesh:

Substances:

Year:  2016        PMID: 27379379     DOI: 10.1007/s12017-016-8421-y

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  49 in total

1.  Essential role for diacylglycerol in protein transport from the yeast Golgi complex.

Authors:  B G Kearns; T P McGee; P Mayinger; A Gedvilaite; S E Phillips; S Kagiwada; V A Bankaitis
Journal:  Nature       Date:  1997-05-01       Impact factor: 49.962

Review 2.  Receptor regulation of osmolyte homeostasis in neural cells.

Authors:  Stephen K Fisher; Anne M Heacock; Richard F Keep; Daniel J Foster
Journal:  J Physiol       Date:  2010-05-24       Impact factor: 5.182

Review 3.  Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system.

Authors:  Y Oda
Journal:  Pathol Int       Date:  1999-11       Impact factor: 2.534

4.  Neuropathy target esterase catalyzes osmoprotective renal synthesis of glycerophosphocholine in response to high NaCl.

Authors:  Morgan Gallazzini; Joan D Ferraris; Margarita Kunin; Ryan G Morris; Maurice B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

5.  Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling.

Authors:  Monowarul M Siddique; Ying Li; Liping Wang; Jianhong Ching; Mainak Mal; Olga Ilkayeva; Ya Jun Wu; Boon Huat Bay; Scott A Summers
Journal:  Mol Cell Biol       Date:  2013-04-01       Impact factor: 4.272

6.  Induced pluripotent stem cells from a spinal muscular atrophy patient.

Authors:  Allison D Ebert; Junying Yu; Ferrill F Rose; Virginia B Mattis; Christian L Lorson; James A Thomson; Clive N Svendsen
Journal:  Nature       Date:  2008-12-21       Impact factor: 49.962

7.  Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase.

Authors:  Xu Hannah Zhang; Chunying Zhao; Konstantin Seleznev; Keying Song; James J Manfredi; Zhongmin Alex Ma
Journal:  J Cell Sci       Date:  2006-02-21       Impact factor: 5.285

8.  Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome.

Authors:  Nupur Nag; Tiffany J Mellott; Joanne E Berger-Sweeney
Journal:  Brain Res       Date:  2008-08-26       Impact factor: 3.252

9.  Rett syndrome as a minicolumnopathy.

Authors:  M F Casanova; D Buxhoeveden; A Switala; E Roy
Journal:  Clin Neuropathol       Date:  2003 Jul-Aug       Impact factor: 1.368

10.  Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model.

Authors:  Angèle Viola; Véronique Saywell; Laurent Villard; Patrick J Cozzone; Norbert W Lutz
Journal:  PLoS One       Date:  2007-01-17       Impact factor: 3.240

View more
  6 in total

Review 1.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

Review 2.  iPSC toolbox for understanding and repairing disrupted brain circuits in autism.

Authors:  Simone Chiola; Nicolas U Edgar; Aleksandr Shcheglovitov
Journal:  Mol Psychiatry       Date:  2021-09-08       Impact factor: 15.992

3.  Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome.

Authors:  Martina Zandl-Lang; Thomas Züllig; Martin Trötzmüller; Yvonne Naegelin; Lucia Abela; Bernd Wilken; Sabine Scholl-Buergi; Daniela Karall; Ludwig Kappos; Harald Köfeler; Barbara Plecko
Journal:  Metabolites       Date:  2022-03-25

Review 4.  Progress in the molecular mechanisms of genetic epilepsies using patient-induced pluripotent stem cells.

Authors:  Ruijiao Zhou; Guohui Jiang; Xin Tian; Xuefeng Wang
Journal:  Epilepsia Open       Date:  2018-07-08

5.  Choline Rescues Behavioural Deficits in a Mouse Model of Rett Syndrome by Modulating Neuronal Plasticity.

Authors:  Eunice W M Chin; Wee Meng Lim; Dongliang Ma; Francisco J Rosales; Eyleen L K Goh
Journal:  Mol Neurobiol       Date:  2018-09-15       Impact factor: 5.590

6.  Sphingolipid Metabolism Perturbations in Rett Syndrome.

Authors:  Gerarda Cappuccio; Taraka Donti; Michele Pinelli; Pia Bernardo; Carmela Bravaccio; Sarah H Elsea; Nicola Brunetti-Pierri
Journal:  Metabolites       Date:  2019-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.